FDANews
FDAnews Device Daily Bulletin

EU Expands CE Mark Indication for Agilent Technologies’ Dako Companion Diagnostics

Feb. 2, 2017

Agilent Technologies has receive an expanded CE mark for its Dako PD-L1 IHC 22C3 pharmDx which can now be used to determine PD-L1 expression status to inform the first-line treatment of metastatic non-small cell lung cancer (NSCLC) patients with Keytruda.

The intended use allows PD-L1 IHC 22C3 pharmDx to detect PD-L1 expression in both untreated and previously treated metastatic patients. — Cynthia Jessup

View today's stories